REZPEGALDESLEUKIN, NOVEL TREG-INDUCING THERAPY, DEMONSTRATES EFFICACY IN ATOPIC DERMATITIS AND ASTHMA IN PHASE 2B TRIAL
Jonathan Corren(California Allergy and Asthma Medical Group), David Rosmarin(Indiana University School of Medicine), Jonathan I. Silverberg(George Washington University), Thomas Bieber(CK-CARE), Raj Chovatiya(Rosalind Franklin University of Medicine and Science), Sohail S. Chaudhry(Nektar Therapeutics (United States)), Maria Hannaway(New York Medical College), Jane Gilbert, P. Lio, Z. Lee, Mario Q. Marcondes(Nektar Therapeutics (United States)), Brian L. Kotzin(Howard Hughes Medical Institute), Adam Reich(Rzeszów University of Technology), Mary Tagliaferri(Nektar Therapeutics (United States)), Spyridon Gkalpakiotis(Charles University), Neil S. Sadick(Cornell University), Christie Fanton(Nektar Therapeutics (United States)), James R. Treat(Children's Hospital of Philadelphia), Soratree Charoenthongtrakul, Ye Liu(Beijing University of Chinese Medicine), Min Zhang(Wuhan Children's Hospital), Danni Yu(National Heart Lung and Blood Institute), Melinda Gooderham(Queen's University), Richard Warren(Manchester Academic Health Science Centre), Jonathan Zalevsky(Nektar Therapeutics (United States))
Cited by 1
Related Papers
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
Lebrikizumab Treatment in Adults with Asthma
|New England Journal of Medicine|2011|1.5k
Atopic dermatitis
|Nature Reviews Disease Primers|2018|1.5k
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
|New England Journal of Medicine|2014|1.4k
Definition of treatment goals for moderate to severe psoriasis: a European consensus
|Archives of Dermatological Research|2010|892